{"brief_title": "Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)", "brief_summary": "To determine what side effects and what clinical effects if any the administration of this investigational product, IDEC-152 (an antibody against CD23 which is an important protein on leukemia cells and certain cells in the body's immune system), has on the CLL patient population.", "condition": ["Chronic Lymphocytic Leukemia"], "intervention_type": ["Drug"], "intervention_name": ["IDEC-152"], "description": ["6 Dosing groups: 125mg/m2 weekly x 4, 250mg/m2 weekly x 4, 375mg/m2 weekly x 4, 500mg/m2 weekly x 4, 500mg/m2 3 times first week then weekly x 3, 500mg/m2 3 times per week x 4"], "other_name": ["Lumiliximab"], "criteria": "Inclusion Criteria: - Signed IRB-approved informed consent. - Greater than 18 years of age - Proof of CD23+ CLL or small lymphocytic lymphoma (SLL) - Progressive disease after at least 1 course of chemotherapy - Acceptable hematologic status, liver function, renal function, and pulmonary function - Patients of reproductive potential must agree to follow accepted birth control methods during treatment and for 3 months after completion of treatment Exclusion Criteria: - Previous exposure to IDEC-152 or other anti-CD23 antibodies - Presence of HIV infection or AIDS - Serious nonmalignant disease - Active uncontrolled bacterial, viral or fungal infections. - Clinically active autoimmune disease - Pregnant or currently breast feeding", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "CLL", "mesh_term": ["Leukemia", "Leukemia, Lymphoid", "Leukemia, Lymphocytic, Chronic, B-Cell"], "id": "NCT00046488"}